Search research articles
Contact Us
Filters
Showing results (251-260 of 323) with videos related to
Page
of 33
Sort By:
JCO Precision Oncology
|
February 1, 2022
Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer
Filippo Pietrantonio, Rona Yaeger, Alexa B Schrock, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 4, 2021
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study
Alessandra Raimondi, Salvatore Corallo, Sara Lonardi, et al.
Cancer Discovery
|
May 6, 2022
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
Giovanni Crisafulli, Andrea Sartore-Bianchi, Luca Lazzari, et al.
Oncology
|
August 22, 2018
Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram
Filippo Pietrantonio, Francesco Barretta, Valentina Fanotto, et al.
Science Translational Medicine
|
May 21, 2025
Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer
Elena Grassi, Valentina Vurchio, George D Cresswell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
Daniele Rossini, Carlotta Antoniotti, Sara Lonardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 3, 2023
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation
Sara Lonardi, Cosimo Rasola, Riccardo Lobefaro, et al.
Journal of the National Cancer Institute
|
September 1, 2021
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications
Roberto Moretto, Andrew Elliott, Jian Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2023
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study
Alessandra A Prete, Paolo Manca, Marco Messina, et al.
The New England Journal of Medicine
|
June 2, 2025
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
Kohei Shitara, Eric Van Cutsem, Mahmut Gümüş, et al.
Page
of 33
Search research articles
Search
Showing results (251-260 of 323) with videos related to
Sort By:
Page
of 33
JCO Precision Oncology
|
February 1, 2022
Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer
Filippo Pietrantonio, Rona Yaeger, Alexa B Schrock, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 4, 2021
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study
Alessandra Raimondi, Salvatore Corallo, Sara Lonardi, et al.
Cancer Discovery
|
May 6, 2022
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
Giovanni Crisafulli, Andrea Sartore-Bianchi, Luca Lazzari, et al.
Oncology
|
August 22, 2018
Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram
Filippo Pietrantonio, Francesco Barretta, Valentina Fanotto, et al.
Science Translational Medicine
|
May 21, 2025
Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer
Elena Grassi, Valentina Vurchio, George D Cresswell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
Daniele Rossini, Carlotta Antoniotti, Sara Lonardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 3, 2023
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation
Sara Lonardi, Cosimo Rasola, Riccardo Lobefaro, et al.
Journal of the National Cancer Institute
|
September 1, 2021
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications
Roberto Moretto, Andrew Elliott, Jian Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2023
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study
Alessandra A Prete, Paolo Manca, Marco Messina, et al.
The New England Journal of Medicine
|
June 2, 2025
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
Kohei Shitara, Eric Van Cutsem, Mahmut Gümüş, et al.
Page
of 33